The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Nonalcoholic Steatohepatitis Diagnostic Market Research Report 2025
Synopsis
Nonalcoholic steatohepatitis (NASH) is liver inflammation and damage caused by a buildup of fat in the liver. It is part of a group of conditions called nonalcoholic fatty liver disease.
Global Nonalcoholic Steatohepatitis Diagnostic market is projected to reach US$ 2043.5 million in 2029, increasing from US$ 1423.5 million in 2022, with the CAGR of 5.3% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Nonalcoholic Steatohepatitis Diagnostic market research.
The nonalcoholic steatohepatitis (NASH) diagnostic market is driven by the increasing prevalence of NASH and the growing awareness of the disease among healthcare providers and patients. NASH is a severe form of nonalcoholic fatty liver disease (NAFLD) characterized by liver inflammation and fibrosis, and it poses a significant global health burden. The rise in obesity rates, sedentary lifestyles, and unhealthy dietary habits contribute to the growing prevalence of NASH. Additionally, advancements in diagnostic technologies, such as non-invasive imaging techniques and blood biomarker assays, have improved early detection and accurate diagnosis of NASH. However, the market also faces challenges, including the lack of specific and validated diagnostic biomarkers for NASH, as well as the need for additional research and clinical validation to establish standardized diagnostic criteria. Moreover, the complex pathophysiology of NASH requires a multi-modal approach to diagnosis, making the development of comprehensive and cost-effective diagnostic strategies a challenge. To succeed in this market, companies must invest in research and development to identify reliable diagnostic biomarkers, collaborate with healthcare providers to improve disease awareness and diagnosis rates, and work towards developing integrated diagnostic algorithms to enhance NASH diagnosis and patient management.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Nonalcoholic Steatohepatitis Diagnostic market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Echosens
Prometheus Laboratories
GENFIT SA
Siemens Medical Solutions USA, Inc.
BioPredictive S.A.S
Quest Diagnostics Incorporated.
Meridian Bioscience, Inc.
Laboratory Corporation of America Holdings
Segment by Type
Serum Biomarkers
Hepatic Fibrosis Biomarkers
Oxidative Stress Biomarkers
Apoptosis Biomarkers
Others
Segment by Application
Pharma & CRO Industry
Hospitals
Academic Research Institutes
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Nonalcoholic Steatohepatitis Diagnostic report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Nonalcoholic steatohepatitis (NASH) is liver inflammation and damage caused by a buildup of fat in the liver. It is part of a group of conditions called nonalcoholic fatty liver disease.
Global Nonalcoholic Steatohepatitis Diagnostic market is projected to reach US$ 2043.5 million in 2029, increasing from US$ 1423.5 million in 2022, with the CAGR of 5.3% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Nonalcoholic Steatohepatitis Diagnostic market research.
The nonalcoholic steatohepatitis (NASH) diagnostic market is driven by the increasing prevalence of NASH and the growing awareness of the disease among healthcare providers and patients. NASH is a severe form of nonalcoholic fatty liver disease (NAFLD) characterized by liver inflammation and fibrosis, and it poses a significant global health burden. The rise in obesity rates, sedentary lifestyles, and unhealthy dietary habits contribute to the growing prevalence of NASH. Additionally, advancements in diagnostic technologies, such as non-invasive imaging techniques and blood biomarker assays, have improved early detection and accurate diagnosis of NASH. However, the market also faces challenges, including the lack of specific and validated diagnostic biomarkers for NASH, as well as the need for additional research and clinical validation to establish standardized diagnostic criteria. Moreover, the complex pathophysiology of NASH requires a multi-modal approach to diagnosis, making the development of comprehensive and cost-effective diagnostic strategies a challenge. To succeed in this market, companies must invest in research and development to identify reliable diagnostic biomarkers, collaborate with healthcare providers to improve disease awareness and diagnosis rates, and work towards developing integrated diagnostic algorithms to enhance NASH diagnosis and patient management.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Nonalcoholic Steatohepatitis Diagnostic market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Echosens
Prometheus Laboratories
GENFIT SA
Siemens Medical Solutions USA, Inc.
BioPredictive S.A.S
Quest Diagnostics Incorporated.
Meridian Bioscience, Inc.
Laboratory Corporation of America Holdings
Segment by Type
Serum Biomarkers
Hepatic Fibrosis Biomarkers
Oxidative Stress Biomarkers
Apoptosis Biomarkers
Others
Segment by Application
Pharma & CRO Industry
Hospitals
Academic Research Institutes
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Nonalcoholic Steatohepatitis Diagnostic report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Nonalcoholic Steatohepatitis Diagnostic Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Serum Biomarkers
1.2.3 Hepatic Fibrosis Biomarkers
1.2.4 Oxidative Stress Biomarkers
1.2.5 Apoptosis Biomarkers
1.2.6 Others
1.3 Market by Application
1.3.1 Global Nonalcoholic Steatohepatitis Diagnostic Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Pharma & CRO Industry
1.3.3 Hospitals
1.3.4 Academic Research Institutes
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Nonalcoholic Steatohepatitis Diagnostic Market Perspective (2018-2029)
2.2 Nonalcoholic Steatohepatitis Diagnostic Growth Trends by Region
2.2.1 Global Nonalcoholic Steatohepatitis Diagnostic Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Nonalcoholic Steatohepatitis Diagnostic Historic Market Size by Region (2018-2023)
2.2.3 Nonalcoholic Steatohepatitis Diagnostic Forecasted Market Size by Region (2024-2029)
2.3 Nonalcoholic Steatohepatitis Diagnostic Market Dynamics
2.3.1 Nonalcoholic Steatohepatitis Diagnostic Industry Trends
2.3.2 Nonalcoholic Steatohepatitis Diagnostic Market Drivers
2.3.3 Nonalcoholic Steatohepatitis Diagnostic Market Challenges
2.3.4 Nonalcoholic Steatohepatitis Diagnostic Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Nonalcoholic Steatohepatitis Diagnostic Players by Revenue
3.1.1 Global Top Nonalcoholic Steatohepatitis Diagnostic Players by Revenue (2018-2023)
3.1.2 Global Nonalcoholic Steatohepatitis Diagnostic Revenue Market Share by Players (2018-2023)
3.2 Global Nonalcoholic Steatohepatitis Diagnostic Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Nonalcoholic Steatohepatitis Diagnostic Revenue
3.4 Global Nonalcoholic Steatohepatitis Diagnostic Market Concentration Ratio
3.4.1 Global Nonalcoholic Steatohepatitis Diagnostic Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Nonalcoholic Steatohepatitis Diagnostic Revenue in 2022
3.5 Nonalcoholic Steatohepatitis Diagnostic Key Players Head office and Area Served
3.6 Key Players Nonalcoholic Steatohepatitis Diagnostic Product Solution and Service
3.7 Date of Enter into Nonalcoholic Steatohepatitis Diagnostic Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Nonalcoholic Steatohepatitis Diagnostic Breakdown Data by Type
4.1 Global Nonalcoholic Steatohepatitis Diagnostic Historic Market Size by Type (2018-2023)
4.2 Global Nonalcoholic Steatohepatitis Diagnostic Forecasted Market Size by Type (2024-2029)
5 Nonalcoholic Steatohepatitis Diagnostic Breakdown Data by Application
5.1 Global Nonalcoholic Steatohepatitis Diagnostic Historic Market Size by Application (2018-2023)
5.2 Global Nonalcoholic Steatohepatitis Diagnostic Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Nonalcoholic Steatohepatitis Diagnostic Market Size (2018-2029)
6.2 North America Nonalcoholic Steatohepatitis Diagnostic Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Nonalcoholic Steatohepatitis Diagnostic Market Size by Country (2018-2023)
6.4 North America Nonalcoholic Steatohepatitis Diagnostic Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Nonalcoholic Steatohepatitis Diagnostic Market Size (2018-2029)
7.2 Europe Nonalcoholic Steatohepatitis Diagnostic Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Nonalcoholic Steatohepatitis Diagnostic Market Size by Country (2018-2023)
7.4 Europe Nonalcoholic Steatohepatitis Diagnostic Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Nonalcoholic Steatohepatitis Diagnostic Market Size (2018-2029)
8.2 Asia-Pacific Nonalcoholic Steatohepatitis Diagnostic Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Nonalcoholic Steatohepatitis Diagnostic Market Size by Region (2018-2023)
8.4 Asia-Pacific Nonalcoholic Steatohepatitis Diagnostic Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Nonalcoholic Steatohepatitis Diagnostic Market Size (2018-2029)
9.2 Latin America Nonalcoholic Steatohepatitis Diagnostic Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Nonalcoholic Steatohepatitis Diagnostic Market Size by Country (2018-2023)
9.4 Latin America Nonalcoholic Steatohepatitis Diagnostic Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Nonalcoholic Steatohepatitis Diagnostic Market Size (2018-2029)
10.2 Middle East & Africa Nonalcoholic Steatohepatitis Diagnostic Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Nonalcoholic Steatohepatitis Diagnostic Market Size by Country (2018-2023)
10.4 Middle East & Africa Nonalcoholic Steatohepatitis Diagnostic Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Echosens
11.1.1 Echosens Company Detail
11.1.2 Echosens Business Overview
11.1.3 Echosens Nonalcoholic Steatohepatitis Diagnostic Introduction
11.1.4 Echosens Revenue in Nonalcoholic Steatohepatitis Diagnostic Business (2018-2023)
11.1.5 Echosens Recent Development
11.2 Prometheus Laboratories
11.2.1 Prometheus Laboratories Company Detail
11.2.2 Prometheus Laboratories Business Overview
11.2.3 Prometheus Laboratories Nonalcoholic Steatohepatitis Diagnostic Introduction
11.2.4 Prometheus Laboratories Revenue in Nonalcoholic Steatohepatitis Diagnostic Business (2018-2023)
11.2.5 Prometheus Laboratories Recent Development
11.3 GENFIT SA
11.3.1 GENFIT SA Company Detail
11.3.2 GENFIT SA Business Overview
11.3.3 GENFIT SA Nonalcoholic Steatohepatitis Diagnostic Introduction
11.3.4 GENFIT SA Revenue in Nonalcoholic Steatohepatitis Diagnostic Business (2018-2023)
11.3.5 GENFIT SA Recent Development
11.4 Siemens Medical Solutions USA, Inc.
11.4.1 Siemens Medical Solutions USA, Inc. Company Detail
11.4.2 Siemens Medical Solutions USA, Inc. Business Overview
11.4.3 Siemens Medical Solutions USA, Inc. Nonalcoholic Steatohepatitis Diagnostic Introduction
11.4.4 Siemens Medical Solutions USA, Inc. Revenue in Nonalcoholic Steatohepatitis Diagnostic Business (2018-2023)
11.4.5 Siemens Medical Solutions USA, Inc. Recent Development
11.5 BioPredictive S.A.S
11.5.1 BioPredictive S.A.S Company Detail
11.5.2 BioPredictive S.A.S Business Overview
11.5.3 BioPredictive S.A.S Nonalcoholic Steatohepatitis Diagnostic Introduction
11.5.4 BioPredictive S.A.S Revenue in Nonalcoholic Steatohepatitis Diagnostic Business (2018-2023)
11.5.5 BioPredictive S.A.S Recent Development
11.6 Quest Diagnostics Incorporated.
11.6.1 Quest Diagnostics Incorporated. Company Detail
11.6.2 Quest Diagnostics Incorporated. Business Overview
11.6.3 Quest Diagnostics Incorporated. Nonalcoholic Steatohepatitis Diagnostic Introduction
11.6.4 Quest Diagnostics Incorporated. Revenue in Nonalcoholic Steatohepatitis Diagnostic Business (2018-2023)
11.6.5 Quest Diagnostics Incorporated. Recent Development
11.7 Meridian Bioscience, Inc.
11.7.1 Meridian Bioscience, Inc. Company Detail
11.7.2 Meridian Bioscience, Inc. Business Overview
11.7.3 Meridian Bioscience, Inc. Nonalcoholic Steatohepatitis Diagnostic Introduction
11.7.4 Meridian Bioscience, Inc. Revenue in Nonalcoholic Steatohepatitis Diagnostic Business (2018-2023)
11.7.5 Meridian Bioscience, Inc. Recent Development
11.8 Laboratory Corporation of America Holdings
11.8.1 Laboratory Corporation of America Holdings Company Detail
11.8.2 Laboratory Corporation of America Holdings Business Overview
11.8.3 Laboratory Corporation of America Holdings Nonalcoholic Steatohepatitis Diagnostic Introduction
11.8.4 Laboratory Corporation of America Holdings Revenue in Nonalcoholic Steatohepatitis Diagnostic Business (2018-2023)
11.8.5 Laboratory Corporation of America Holdings Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
